Last update Jan. 28, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
チオコルチコシド is Thiocolchicoside in Japanese.Is written in other languages:
チオコルチコシド belongs to this group or family:
Main tradenames from several countries containing チオコルチコシド in its composition:
|VD||0.4 - 0.6||l/Kg|
|Tmax||0.5 - 1||hours|
|T½||1.5 - 7||hours|
Write us at email@example.com
e-lactancia is a resource recommended by Asociación Pro Lactancia Materna (APROLAM) of Mexico
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Muscle-relaxant drug which is marketed in some countries and usually associated to acetaminophen.
Oral administration twice a day.
Since the last update we have not found any published data on its excretion in breast milk.
Seizures have been described in a 3-month-old infant on the third day the mother took 8 mg of thiocolchicoside daily (Havali 2019).
Convulsions have been reported in susceptible persons (Giavina 2009, De Riu 2001).
There is a warning on likely mutagenic effects with a prolonged use. European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection (EMA 2013).
It is a drug with very few bibliographic references.